Glaucoma Therapeutics Market Clinical Review, Drug Descriptions, Analysis and Synthesis 2026

Glaucoma Therapeutics Market
Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018–2026
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Glaucoma Therapeutics Market Overview
Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field
loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the
International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of
blindness and leading cause of irreversible blindness worldwide. The most common types of
glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma
(PACG). Moreover, PACG is most common in South-East Asian population while POAG is most
common in white Caucasians and individuals of African origin. PACG is associated with a high
risk of blindness as compared to POAG.
A sample of this report is available upon request:
https://www.coherentmarketinsights.com/insight/request-sample/1731
Increasing number of patients with glaucoma and increasing incidences of blindness are
expected to be the major driving factor for growth of the global glaucoma therapeutics market.
According to the International Agency for the Prevention of Blindness, 2010 data findings, it is
estimated that by 2020, around 80 million people will suffer from glaucoma, with an increase of
about 20 million form 2010. Furthermore, in 2010, over 8 million people were bilaterally blind
due to glaucoma, which is expected to increase to over 11 million by 2020. The significant risk of
developing glaucoma increases with geriatric population, increased intraocular pressure,
positive family history for glaucoma, and ethnicity. According to the American Academy of
Ophthalmology (AAO), 2016: the global prevalence of glaucoma is estimated to rise to 76 million
in 2020 and 111.8 million in 2040.
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
Glaucoma may occur among the people with or without diabetes. Moreover, people
with diabetic retinopathy have an increased risk of glaucoma. The condition is
associated with abnormal blood vessel growth, which can result in retinopathy and
leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population
is one of the important factors for increasing prevalence of glaucoma, which in turn is
projected to drive growth of the glaucoma therapeutics market in near future. For
instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the
number of people with diabetes aged between 20 to 79 years are increasing worldwide.
Among which, Africa (156%) is accounted to register the highest diabetic population,
followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%),
North America (35%), Europe (16%), and Western Pacific (15%).
On the basis of region, glaucoma therapeutics market is segmented into North
America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North
America holds dominant position in glaucoma therapeutics market, followed by
Asia Pacific. Increasing prevalence of diabetes, increasing ocular disorders, and
increasing number of blind and visually impaired people in turn opting for
glaucoma treatment are expected to drive growth of the glaucoma therapeutic
market in these region.
Browse Research Report At:
https://www.coherentmarketinsights.com/ongoing-insight/glaucoma-therapeutics-market-1675
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION
For instance, According to National Federation of the Blind, 2014, an estimated 10 million
people in the U.S. are blind or visually impaired. It is estimated that around 1.3 million people
are legally blind in the U.S. and the number is projected to increase to 75,000 people annually in
the U.S.
Asia Pacific is expected to gain a significant traction over the forecast period, owing to the
government initiatives and awareness programs to eliminate the blindness, which in turn is
propelling demand for glaucoma therapies in this region. For instance, in 2014, HelpAge India—
a nonprofit organization—launched a special campaign to address the issue of blindness for
underprivileged elderly populations of India.
Get Exclusive Discount on this CMI Report:
https://www.coherentmarketinsights.com/insight/request-discount/1675
Some of the key players operating in the glaucoma therapeutics market include Valeant
Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva
Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen
Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. Key players in the market
are focusing on organic growth strategies in order to gain maximum market share and retain
leading position in the market. For instance, in December 2017, Aerie Pharmaceuticals, Inc.
received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil
ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular hypertension.
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS
ABOUT US
Coherent Market Insights is a global market intelligence and consulting organization focused on
assisting its plethora of clients achieve transformational growth by helping them make critical business
decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our
client base includes players from across all business verticals in over 150 countries worldwide. We are
uniquely positioned to help businesses around the globe deliver practical and lasting results through
various recommendations about operational improvements, technologies, emerging market trends and
new working methods. We offer both customized and syndicated market research reports that help our
clients create visionary growth plans to provide traction to their business. We meticulously study
emerging trends across various industries at both the global and regional levels to identify new
opportunities for our clientele.
SERVICES
INDUSTRY ANALYSIS
CUSTOMIZED
RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE
SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC
STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI
SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry
 Component Providers and System Integrators
 Private and Government organization
 Distributors, Retailors and Value Added Resellers
 Outsourcing Companies
 Healthcare IT Solutions Developers
 Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY
STUDIES
Insights Published
Per Year
GLOBAL
REPORTS
150+
Consulting Projects
Till Date
COUNTRY
ANALYSIS
CONSULT
PROJECTS
125+
Clients Worldwide
Per Year
110+
SURVEY
RESEARCH
EXCEL
FORECAST
DATABASE
CUSTOMIZED
SOLUTIONS
COMPETITIVE
ASSESSMENT
TECHNOLOGY
SNIPPETS
Analysts and Contract
Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals,
including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in
order to result in the best possible market research reports across various industries worldwide. Based on our unmatched
expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better
outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure
sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of
opportunities posed therein.
© Coherent market Insights. All Rights Reserved
THANK YOU
To know more about us, visit our website:
www.coherentmarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Mr. Shah
(Manager - Business Development)
Coherent Market Insights
[email protected]
+1-206-701-6702
© Coherent market Insights. All Rights Reserved

Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG. To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/ongoing-insight/toc/1675